BCTX — Briacell Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $11.92m
- $10.72m
2019 July 31st | 2020 July 31st | C2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.146 | 0.019 | 57.3 | 41 | 21.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.003 | 0.021 | 0.013 | 0.024 | 0.019 |
Prepaid Expenses | |||||
Total Current Assets | 0.157 | 0.239 | 57.8 | 42.3 | 26.9 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 0.414 | 0.478 | 58 | 42.6 | 27.2 |
Accounts Payable | |||||
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.755 | 3.63 | 0.557 | 0.941 | 1.8 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.06 | 3.77 | 30.4 | 32.2 | 30.9 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.642 | -3.3 | 27.7 | 10.3 | -3.78 |
Total Liabilities & Shareholders' Equity | 0.414 | 0.478 | 58 | 42.6 | 27.2 |
Total Common Shares Outstanding |